Trials / Completed
CompletedNCT00092807
Sitosterolemia Extension Study (0653-003)(COMPLETED)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label Extension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
This is an extension study for patients having unusually high absorption of non-cholesterol sterols, resulting in heart-related diseases. This study will evaluate the long term safety and the ability to lower cholesterol levels with an investigational drug.
Detailed description
The duration of treatment is 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0653, ezetimibe | |
| DRUG | Comparator: placebo |
Timeline
- Start date
- 2001-02-12
- Primary completion
- 2001-09-18
- Completion
- 2004-11-30
- First posted
- 2004-09-28
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00092807. Inclusion in this directory is not an endorsement.